8 March 2018 - - Ridgefield, Connecticut-based Boehringer Ingelheim Pharmaceuticals, the US subsidiary of Boehringer Ingelheim Corp., and Indianapolis, Indiana-based global pharmaceuticals specialist Eli Lilly and Company (NYSE: LLY) plan to expand their clinical trial program for Jardiance in chronic heart failure with the EMPERIAL clinical trials, the companies said.
These trials will evaluate the effect of Jardiance on exercise ability and heart failure symptoms in people with chronic heart failure independent of whether they have type 2 diabetes.
EMPERIAL consists of two Phase III randomized, double-blind trials that will assess the effect of 12 weeks of treatment with once-daily Jardiance 10 mg compared with placebo on exercise ability and heart failure symptoms in patients with chronic heart failure with preserved or reduced ejection fraction, as measured by the 6-minute walk test.
EMPERIAL-preserved will investigate Jardiance in patients with chronic heart failure with preserved ejection fraction (HFpEF).
EMPERIAL-reduced will investigate Jardiance in patients with chronic heart failure with reduced ejection fraction (HFrEF).
Jardiance is a prescription medicine used along with diet and exercise to lower blood sugar in adults with type 2 diabetes. It is also used to reduce the risk of cardiovascular death in adults with type 2 diabetes who have known cardiovascular disease.
Boehringer Ingelheim Pharmaceuticals is the largest US subsidiary of Boehringer Ingelheim Corp., headquartered in Ingelheim, Germany. The company operates globally with approximately 50,000 employees in three business areas including human pharmaceuticals, animal health, and biopharmaceutical contract manufacturing.
Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism.